Side-by-side · Research reference

CartalaxvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Cartalax

VIP

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

VIP

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

VIP

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

VIP

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Cartalax

VIP

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Inhaled protocol (investigational)

—

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.